Leaflet MIGEA RAPID 200mg tablets
Indicated for: migraine; pain
Route of administration: oral
Substance: tolfenamic acid (nonsteroidal anti-inflammatory drug)
ATC: M01AG02 (Musculo-skeletal system | Antiinflammatory and antirheumatic products, non-steroids | Fenamates)
This medicine may have important interactions with other medicines.
This medicine may affect the kidneys.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
This medicine may increase the risk of ulcer or gastrointestinal bleeding.
Tolfenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for the treatment of acute migraines and moderate pain. It works by inhibiting cyclooxygenase (COX-1 and COX-2), thereby reducing the production of prostaglandins, substances involved in inflammation, pain, and fever.
It is effective in relieving migraine-related pain and can also be used for other inflammatory conditions, including muscle and joint pain. Compared to other NSAIDs, tolfenamic acid has similar efficacy but may offer a better tolerability profile for some patients.
It is taken orally and has a rapid absorption, with analgesic effects occurring within an hour. It can be used as an alternative to other NSAIDs, such as ibuprofen or naproxen, especially in patients who have responded well to this compound.
Side effects may include nausea, stomach discomfort, heartburn, dizziness, and, in rare cases, severe allergic reactions or kidney impairment. It is not recommended for patients with a history of severe gastric ulcers, renal failure, or cardiovascular conditions without medical supervision.
General data about MIGEA RAPID 200mg
- Substance: tolfenamic acid
- Date of latest medicines list: 01-07-2013
- Product code: W13273001
- Concentration: 200mg
- Pharmaceutical form: tablets
- Quantity: 10
- Product type: Generic medicine
- Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.